The b-adrenoceptors (ARs) have been classified originally into two subtypes, i.e., b 1 -and b 2 -ARs. 1) In 1984, Arch et al. developed a novel b 3 -AR agonist BRL 37344, and showed that it was more potent at stimulating lipolysis than at increasing the heart rate or causing tracheal smooth muscle relaxation.
2) Another b-subtype, b 4 -AR, has also been reported in the mammalian heart.
3) But later, this subtype was declared a novel state of the b 1 -AR. 4) These belong to a large family of G-protein-coupled receptors (GPCRs) that are characterized by seven transmembrane helices. b-Adrenergic stimulation activates plasma membrane adenylyl cyclase, resulting in an elevation of intracellular cyclic AMP which mediates a number of hormone-induced responses. b 3 -Adrenergic stimulation is known to mediate catecholamine action on the metabolic processes in skeletal muscle 5) and adipose tissue, 1, 6, 7) on glucose and serum insulin levels in obese and diabetic mice, [8] [9] [10] on smooth muscle relaxation in the digestive tract, 11) and to exert hypotensive effects and increased cardiac contractility in vivo in hypertensive dogs. 12) Selective drugs for a certain receptor subtype have been useful tools in the studies of drug-receptor interaction and receptor-mediated physiological responses in tissues expressing a variety of receptors. The introduction of a selective b 3 -AR agonist with high intrinsic activity should help understand the functional role of b 3 -AR in various tissues, including the heart.
In the present study, we have performed binding and functional studies of a newly synthesized compound, SWR-0315NA (Fig. 1) , with the goal of obtaining a potent b 3 -AR agonist. These experiments have focused upon characteristic pharmacological properties of human b 3 -AR subtypes, including ligand binding affinity and coupling to cAMP generation. We report the compound SWR-0315NA as having potent b 3 -AR agonistic activity.
MATERIALS AND METHODS

Materials
The compound SWR-0315NA used in the present study was synthesized in the laboratory of Sawai Pharmaceuticals Co., Ltd. (Osaka, Japan). (Ϫ)-Isoproterenol hydrochloride, 3-isobutyl-1-methylxanthine (IBMX) and bovine serum albumin fraction V were purchased from Sigma (St. Louis, MO, U.S.A.). Ham's F-12 medium was purchased from Nissui Pharmaceutical Co., Ltd. (Tokyo, Japan). Fetal bovine serum was purchased from Biowhittaker (Maryland, U.S.A.). cAMP enzyme immunoassay kit was purchased from Shibayagi Co., Ltd. (Gunma, Japan). [ 125 I]Iodocyanopindolol (1.85 TBq/mmol) was purchased from New England Nuclear Corp. (Tokyo, Japan). All other chemicals used were of the highest purity available.
Expression of b b-AR Subtypes in COS-7 Cells b 1 -, b 2 -and b 3 -AR were transiently expressed in COS-7 cells by the method described by Sato et al. 13) Briefly, human b-AR subtypes in pEF-BOS were transfected into COS-7 cells using the DEAE-dextran method.
14) The DNA sequences encoding the human b-AR subtypes were amplified from the genomic DNA prepared from HeLa cells. Any error in the sequences was determined by the polymerase chain reaction (PCR) and was corrected thereafter. The resulting constructs were inserted into the mammalian expression vector pEF-BOS. 15) COS-7 cells (3ϫ10 6 ) were seeded on a 100 mm tissue culture dish the day before transfection. To each subconfluent plate, 1.5 mg of the DNA is added together with DEAE-dextran. The transfected cells were grown as monolayers in a 100 mm dish containing Dulbecco's Modified Eagle's Medium supplemented with 5% fetal bovine serum and gentamicin (10 mg/ml) under an atmosphere of 95% air and 5% CO 2 at 37°C.
Membrane Preparations from COS-7 Cells Forty- eight hours after the transfection, the COS-7 cells were rinsed with 10 ml of ice-cold phosphate-buffered saline (PBS) and mechanically detached by ultrasonication in 5 ml of lysis buffer containing 5 mM Tris-HCl (pH 7.4), 2 mM EDTA, 5 mg/ml soybean trypsin inhibitor, 5 mg/ml leupeptin and 10 mg/ml benzamidine. The COS-7 cells were homogenized using a glass homogenizer and were centrifuged at 45000ϫg for 30 min at 4°C. The resultant membrane fractions were resuspended in a lysis buffer and frozen at Ϫ80°C until used.
Radioligand Binding Assay COS-7 cells were chosen for the binding experiment because of the high receptor expression levels commonly achieved in this system. 16) Radioligand binding studies were carried out in an assay buffer containing 75 mM Tris-HCl (pH 7.4), 12.5 mM MgCl 2 and 2 mM EDTA at 37°C for 60 min using 5-10 mg of membrane protein. The total reaction volume was 250 ml. ]iodocyanopindolol. The reactions were stopped by dilution with 4 ml cold wash buffer containing 25 mM Tris (pH 7.5) and 1 mM MgCl 2 , and rapid filtration over Whatman GF/C glass fiber filters. The filters were washed with an additional ice-cold wash buffer (4 ml). The radioactivity remaining on the filter was counted by a gamma scintillation counter.
Expression of b b-AR Subtypes in CHO Cells
Standard cloning techniques were used for the expression of human b 1 -, b 2 -and b 3 -AR in CHO cells, as described by Maniatis et al. 17) The human b-AR subtypes cDNA were each obtained by reverse transcription and PCR amplification from human placenta mRNA, in accordance with the method described by Granneman et al. 18) Each of the PCR products was cloned into expression vector pAP3 neo. The nucleotide sequences of each were verified with those of the human b-AR subtypes cDNA sequences. CHO cells were transfected with each of the pAP3 neo containing the human b 1 -, b 2 -and b 3 -AR cDNA using the calcium-phosphate precipitation technique. Stable transfectants with human b-AR subtypes (b 1 -, b 2 -and b 3 -CHO cells) were obtained by culture of the cells in Ham's F-12 medium supplemented with penicillin (100 U/ml), streptomycin (100 mg/ml), fetal bovine serum (10% v/v) and G418 (1 mg/ml).
Assay of cAMP Accumulation G-protein mediated agonist stimulation of adenylyl cyclase can be analyzed in the CHO cell system, as it does not exhibit catecholamine-stimulated cAMP stimulation. 16) This approach is not feasible in COS-7 cells and, therefore, for the assay of adenylyl cyclase we turned our attention to the CHO cell system.
Adenylyl cyclase stimulation was determined by the accumulation of cAMP according to the method of Blin et al. with some modification. 19) Briefly, stably transfected CHO cells were grown to preconfluence in a 96-well microplate (about 5ϫ10 4 -free phosphate buffered saline (PBS(Ϫ)) and by the immediate addition of 100 ml of 1 N NaOH. After a period of 20 min at 37°C, the dissolved cells were neutralized with 100 ml of 1 N acetic acid and centrifuged at 3000ϫg for 10 min at 4°C. The concentration of cAMP in the supernatant was measured by the cAMP enzyme immunoassay system using the double antibody method. The adenylyl cyclase stimulations to SWR-0315NA were expressed as a percentage of the maximum response obtained with (Ϫ)-isoproterenol.
Protein Assay Protein contents of the membrane concentration were measured by the method of Lowry et al. using bovine serum albumin as the standard. 21) EC 50 (or K act ) parameters (concentration of agonist required to elicit 50% of the maximum response for (Ϫ)-isoproterenol in a particular clone cell) obtained from adenylyl cyclase activation were determined using computer software (GraphPad Prism version 3.00 for Windows, GraphPad Software, San Diego, California, U.S.A.). Student's paired t-test was performed to assess the significance of the difference. A p value of less than 0.05 was taken as significant.
RESULTS
Newly synthesized compound SWR-0315NA was evaluated for its potency at 
DISCUSSION
The development of various compounds that have high activity for human b 3 -AR is still underway. We constructed cells of COS-7 and CHO which transiently and stably, respectively, express human b 1 -, b 2 -and b 3 -AR, and evaluated the selectivity of a newly synthesized compound, SWR-0315NA, towards these subtypes of b-AR.
The present study examined the displacement potencies of (Ϫ)-isoproterenol and SWR-0315NA for [ Table 1 ). The affinity of (Ϫ)-isoproterenol for b 3 -AR is 5-fold greater than that of SWR-0315NA.
With adenylyl cyclase assays in CHO cells transfected with human b 1 -, b 2 -and b 3 -AR, (Ϫ)-isoproterenol had 9-fold and 10-fold higher potencies for b 3 -AR against b 1 -and b 2 -AR. SWR-0315NA had 26-fold and more than 630-fold 720 Vol. 27, No. 5 Values indicated are meansϮS.E.M of the n number of experiments. %Emax is the maximum cAMP accumulation stimulated by the compounds relative to that of (Ϫ)-isoproterenol ϫ100. -AR subtypes with different affinities, the potencies (EC 50 ) of (Ϫ)-isoproterenol to stimulate adenylyl cyclase are similar between b 1 -and b 2 -AR, and higher than in the b 3 -AR mediated pathways. The potency of an agonist is determined by the affinity of the agonist for the receptor, and by the coupling between the receptor and the G protein. It is assumed that the latter depends on the structure of the receptor, especially intracellular domains, but not ligands. 22) The vast discrepancy between the affinity of (Ϫ)-isoproterenol for b 2 -AR and the coupling of the receptor with Gs protein upon (Ϫ)-isoproterenol stimulation is presumably due to the intrinsic difference in the strength of coupling between the receptor, i.e., b 2 -AR and the Gs protein. Affinity measured by ligand binding assays does not predict potency in functional assays, particularly in intact cell assays. 23) In this context, it should be noted that the b 3 -AR showed higher efficiency in the agonist-promoted coupling between the receptor and the Gs protein than the b 1 -and b 2 -ARs did for SWR-0315NA.
There were no correlations between specific [ 125 I]ICYP binding and cAMP accumulation by (Ϫ)-isoproterenol and SWR-0315NA in COS-7 and CHO cells expressing b-AR subtypes, respectively. This discrepancy should not be explained in the light of different receptor expression systems; rather, the receptor occupancy of the ligands should be taken into account. In a few cases, the pK i values and pK act values are almost the same, but in most cases there are differences that account for the maximal activation of adenylyl cyclase by the b-AR subtype when relatively few receptors are occupied. Granneman 24) and Wilson et al. 23) reported that the high efficiency of b 3 -AR coupling to cAMP generation is indicated by a large discrepancy between K i and EC 50 which occurs at various levels of receptor expression and is present in cells that natively express the receptor. It implies that binding with few sites on the receptor may promote cAMP accumulation to a large extent. SWR-0315NA has a lower binding affinity for b 3 -AR, but it also has a low EC 50 value for cAMP accumulation.
Characterization of b 3 -AR in the heart has opened new fields of investigations for the understanding of cardiac adrenergic regulation. The present results indicate that SWR-0315NA has comparatively higher potency and efficacy towards b 3 -AR, and that it could be a potential agonist for further investigation of b 3 -AR properties.
In summary, the present study shows that compound SWR-0315NA is a potential agonist for b 3 -AR by radioligand binding assay and cAMP accumulation assay. The com- pound has been found to be a highly potent b 3 -AR agonist, which has a %Emax value of 93.2 relative to (Ϫ)-isoproterenol. Despite a lower %Emax value than (Ϫ)-isoproterenol, SWR-0315NA is selective to b 3 -AR, unlike (Ϫ)-isoproterenol. Further investigation of its functional activity in native tissues with b 3 -AR subtypes could be useful for defining the physiological roles of b 3 -AR.
